Economic burden of HIV and TB/HIV coinfection in a middle-income country: a costing analysis alongside a pragmatic clinical trial in Brazil

dc.creatorSiqueira-Filha, Noemia Teixeira de
dc.creatorAlbuquerque, Maria de Fatima Militao de
dc.creatorRodrigues, Laura Cunha
dc.creatorLegood, Rosa
dc.creatorSantos, Andreia Costa
dc.date2019-05-10T13:31:39Z
dc.date2019-05-10T13:31:39Z
dc.date2018
dc.date.accessioned2023-09-26T23:43:26Z
dc.date.available2023-09-26T23:43:26Z
dc.identifierTEIXEIRA DE SIQUEIRA-FILHA, N. et al. Economic Burden of HIV and TB/HIV Coinfection in a Middle-Income Country: A Costing Analysis alongside a Pragmatic Clinical Trial in Brazil. Sexually Transmitted Infections, v. 94, n. 6, p. 463–469, 2018.
dc.identifier1472-3263
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/33032
dc.identifier10.1136/sextrans-2017-053277
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8893543
dc.descriptionInstituto de Tecnologia em Saúde Avaliação (IATS).
dc.descriptionObjective The objective of this study was to measure the costs of people living with HIV (PLHIV) as well as active tuberculosis (TB/HIV), latent tuberculosis infection (LTBI/HIV) or without TB (HIV/AIDS). Methods We analysed the costs through the entire pathway of care during the prediagnosis and treatment periods from the Brazilian public health system perspective. We applied a combination of bottom-up and top-down approaches to capture and estimate direct medical and non-medical costs. We measured the mean cost per patient per type of care (inpatient, outpatient and emergency care) and disease category (HIV/AIDS, HIV/AIDS death, TB/HIV, TB/HIV death and LTBI/HIV). Results Between March 2014 and March 2016 we recruited 239 PLHIV. During the follow-up 26 patients were diagnosed and treated for TB and 5 received chemoprophylaxis for LTBI. During the prediagnosis and treatment period, the mean total costs for HIV or AIDS and AIDS death categories were US$1558 and US$2828, respectively. The mean total costs for TB/HIV and TB/ HIV death categories were US$5289.0 and US$8281, respectively. The mean total cost for the LTBI/HIV category was US$882. Conclusions Patients with TB/HIV impose a higher economic burden on the health system than HIV/AIDS and LTBI/HIV. Patients with LTBI/HIV were the lowest cost group among all disease categories, indicating that preventive TB treatment can avoid the further costs treating active TB.
dc.description2050-01-01
dc.formatapplication/pdf
dc.languageeng
dc.rightsrestricted access
dc.subjectLatent Tuberculosis
dc.subjectBrazil
dc.subjectCoinfection
dc.subjectCost of Illness
dc.subjectCosts and Cost Analysis
dc.subjectHIV Infections
dc.subjectHealth Services Research
dc.subjectAdulto
dc.subjectBrasil / epidemiologia
dc.subjectCoinfecção / economia
dc.subjectCoinfecção / epidemiologia
dc.subjectCustos e Análise de Custo
dc.subjectFêmea
dc.subjectInfecções por HIV / economia
dc.subjectInfecções por HIV / epidemiologia
dc.subjectHumanos
dc.subjectRenda
dc.subjectTuberculose Latente / epidemiologia
dc.subjectMasculino
dc.subjectMeia idade
dc.subjectAdulto jovem
dc.titleEconomic burden of HIV and TB/HIV coinfection in a middle-income country: a costing analysis alongside a pragmatic clinical trial in Brazil
dc.typeArticle


Este ítem pertenece a la siguiente institución